 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| mometasone fuorate (LYR-210) / Lyra Therap
Trial completion date, Trial primary completion date: Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2) (clinicaltrials.gov) - Oct 27, 2023
P3, N=180, Recruiting, Sponsor: Lyra Therapeutics
Trial completion date: Jan 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Dec 2024
- |||| mometasone fuorate (LYR-210) / Lyra Therap
Enrollment closed, Trial completion date, Trial primary completion date: ENLIGHTEN 1: Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (clinicaltrials.gov) - Sep 11, 2023
P3, N=180, Active, not recruiting, Sponsor: Lyra Therapeutics
Trial completion date: Jan 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Dec 2024 Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: Aug 2023 --> Mar 2024
- |||| mometasone fuorate (LYR-210) / Lyra Therap
Enrollment open: Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2) (clinicaltrials.gov) - Apr 26, 2023
P3, N=180, Recruiting, Sponsor: Lyra Therapeutics
Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: Aug 2023 --> Mar 2024 Active, not recruiting --> Recruiting
- | mometasone fuorate (LYR-210) / Lyra Therap
Journal, HEOR: Impact of long-acting implantable LYR-210 corticosteroid matrices on quality of life of patients with chronic rhinosinusitis in the LANTERN study. (Pubmed Central) - Feb 8, 2023
Long-acting, local anti-inflammatory treatments that improve the QoL of CRS patients are needed. LYR-210 (7500?g) significantly improved scores for SNOT-22 subdomains and SF-36v2 at week 24.
- |||| mometasone fuorate (LYR-210) / Lyra Therap
Enrollment closed: Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2) (clinicaltrials.gov) - Nov 30, 2022
P3, N=180, Active, not recruiting, Sponsor: Lyra Therapeutics
LYR-210 (7500?g) significantly improved scores for SNOT-22 subdomains and SF-36v2 at week 24. Recruiting --> Active, not recruiting
- || mometasone fuorate (LYR-210) / Lyra Therap
Clinical, PK/PD data, Journal: Pharmacokinetic Evidence of Steady and Sustained Drug Release from Long-Acting Implantable Corticosteroid Matrices for Chronic Rhinosinusitis. (Pubmed Central) - Oct 12, 2022
Recruiting --> Active, not recruiting LYR-210 achieved dose-dependent, continuous local MF delivery at a steady rate with low systemic exposure for months.
- |||| mometasone fuorate (LYR-210) / Lyra Therap
Enrollment open: Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2) (clinicaltrials.gov) - May 26, 2022
P3, N=180, Recruiting, Sponsor: Lyra Therapeutics
LYR-210 achieved dose-dependent, continuous local MF delivery at a steady rate with low systemic exposure for months. Not yet recruiting --> Recruiting
- || mometasone fuorate (LYR-210) / Lyra Therap
Clinical, P2 data, Journal: Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study. (Pubmed Central) - Apr 22, 2022
Not yet recruiting --> Recruiting LYR-210 is the first implantable sinonasal treatment to achieve up to 24 weeks of benefit from a single administration in surgically naive CRS patients with and without nasal polyps.
- |||||||| mometasone fuorate (LYR-210) / Lyra Therap
New P3 trial: Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2) (clinicaltrials.gov) - Mar 25, 2022
P3, N=180, Not yet recruiting, Sponsor: Lyra Therapeutics
- ||| mometasone fuorate (LYR-210) / Lyra Therap
Enrollment change: LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study) (clinicaltrials.gov) - Mar 23, 2022
P2, N=71, Completed, Sponsor: Lyra Therapeutics
LYR-210 is the first implantable sinonasal treatment to achieve up to 24 weeks of benefit from a single administration in surgically naive CRS patients with and without nasal polyps. N=191 --> 71
- |||||||| mometasone fuorate (LYR-210) / Lyra Therap
New P3 trial: ENLIGHTEN 1: Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (clinicaltrials.gov) - Feb 2, 2022
P3, N=180, Recruiting, Sponsor: Lyra Therapeutics
- ||| mometasone fuorate (LYR-210) / Lyra Therap
Trial completion, Enrollment change: LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study) (clinicaltrials.gov) - Jan 5, 2022
P2, N=191, Completed, Sponsor: Lyra Therapeutics
N=191 --> 71 Active, not recruiting --> Completed | N=110 --> 191
- || mometasone fuorate (LYR-210) / Lyra Therap
Enrollment closed: LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study) (clinicaltrials.gov) - May 14, 2020
P2, N=110, Active, not recruiting, Sponsor: Lyra Therapeutics
Active, not recruiting --> Completed | N=110 --> 191 Recruiting --> Active, not recruiting
- || mometasone fuorate (LYR-210) / Lyra Therap
Clinical, P1 data, Journal: Phase 1 clinical study to assess the safety of a novel drug delivery system providing long-term topical steroid therapy for chronic rhinosinusitis. (Pubmed Central) - Feb 1, 2020
Recruiting --> Active, not recruiting LYR-210 is safe and well-tolerated in ESS-naive CRS patients and leads to sustained symptom improvement in patients.
- | mometasone fuorate (LYR-210) / Lyra Therap
New P2 trial: LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study) (clinicaltrials.gov) - Jul 31, 2019
P2, N=110, Recruiting, Sponsor: Lyra Therapeutics